| Line | All comers |
|---|
| Early / localised | 1 |
| Advanced, first line | 1 |
| Second line | 1 |
| Other settings | 1 |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Resectable | Surgery with or without perioperative chemotherapy, whose benefit is doubtful here; neoadjuvant immunotherapy (nivolumab-ipilimumab, durvalumab-tremelimumab) in trials or where available. | | | 98 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Advanced, first line | PD-1 antibody with or without chemotherapy (nivolumab or pembrolizumab); nivolumab with ipilimumab in selected patients; the benefit exceeds that in any other subgroup. | | | 98 |
Second line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Advanced, after chemotherapy | Pembrolizumab under its tumour-agnostic approval for mismatch repair-deficient cancers. | | | 98 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Hereditary risk | Germline testing and Lynch syndrome surveillance where the pattern suggests it. | | | 94 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.